We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byFaith Knight
Modified over 3 years ago
Pharmaceutical Policy and Pricing: How are Countries Getting Greater Value? Commonwealth Fund/ Alliance for Health Reform Briefing on Capitol Hill Dr. jur. Rainer Hess Federal Joint Committee, Germany (G-BA) Page 1 | 7th November 2011 | Commonwealth Fund/ Alliance for Health Reform© 2011, Dr. jur. Rainer Hess
Pharmaceutical Policy and Pricing Page 2 | 7th November 2011 | Commonwealth Fund/ Alliance for Health Reform© 2011, Dr. jur. Rainer Hess Development of RX drug sales and prices (index Q1/2007) Generic drugsOn patent drugs Source: NVI (INSIGHT Health); pharmacy retail prices (Apothekenverkaufspreise).
A.State/Federal Physicians organisation B. State/Federal Hospital organisation C. State/Federal Sickness Fund-Ass. Patient / Insuree Decision Platform for defining the services delivered as statutory health insurance Federal Joint Committee (G-BA) A. C. B. Patient Organisations Advisory membership Institut for Quality and Efficiency (IQWiG) Commissioning Legal Framework for Healthcare established by law and the Ministry of Health Pharmaceutical Policy and Pricing Page 3 | 7th November 2011 | Commonwealth Fund/ Alliance for Health Reform© 2011, Dr. jur. Rainer Hess Industry: Transparency of assessments and drafts of decisions; written and oral hearings; justified decisions; right to sue
Pharmaceutical Policy and Pricing Pharmaceutical steering tools: 1.Federal level: Reference price setting for comparable drugs including patented drugs Early assessment of new pharmaceutical agents within 6 months after market access and based on the assessed value (started in 2011) Negotiation or setting of a reimbursement price 12 months after market access (starts in 2012) Exclusion of drugs in case of inappropriateness compared with treatment alternatives OTC-exemption list; lifestyle-negative list Page 4 | 7th November 2011 | Commonwealth Fund/ Alliance for Health Reform© 2011, Dr. jur. Rainer Hess
Pharmaceutical steering tools: 2. State level: Negotiation of savings goals on the basis of DDD- recommendations IT-based drug prescribing check of physicians Discount negotiations between sickness funds and pharmaceutical companies based on tendering procedures including the possibility of risk-sharing and price-volume payback agreements Binding on the pharmacists to dispend a discount negotiated drug, if the physician does not exclude aut similar. Pharmaceutical Policy and Pricing Page 5 | 7th November 2011 | Commonwealth Fund/ Alliance for Health Reform© 2011, Dr. jur. Rainer Hess
Manu- facturer Market access Manu- facturer Market access G-BA Efficiency assessment (published) G-BA Efficiency assessment (published) IQWIQ Control and assessment Evaluation request G-BA Manufacturers price Free price setting Prepares assessment Submits dossier G-BA Efficiency assessment decision G-BA Efficiency assessment decision Manufact./ Head associa. statutory health ins. Price negotiation Manufact./ Head associa. statutory health ins. Price negotiation Arbitration authority Arbitral verdict Arbitration authority Arbitral verdict IQWIQ Cost-benefit assessment IQWIQ Cost-benefit assessment Hearing manuf. experts Add. Benefit No agreement Not accepted Reference price Maximum GKV reimbursement price Reference price Maximum GKV reimbursement price Market access No add. Benefit No reference price applicable Agreement Rebate Freely decided on Rebate Freely decided on Rebate On ex-factory price Rebate On ex-factory price Retro- active Valid until the end of the procedure 3 months6 months12 months15 months Pharmaceutical Policy and Pricing We are here Page 6 | 7th November 2011 | Commonwealth Fund/ Alliance for Health Reform© 2011, Dr. jur. Rainer Hess
Free market access of a new pharmaceutical 2. Reference prices 8. OTC exemption list 6. Prescription restrictions 7. Therapeutical advice 3. Reimbursement price agreements for new pharmaceuticals with additional benefit 4. Cost-benefit assessment (second line) 1. Early benefit assessment of new pharmaceuticals 5. Subsequent benefit assessment Health care research/ Health care studies Pharmaceutical Policy and Pricing Page 7 | 7th November 2011 | Commonwealth Fund/ Alliance for Health Reform© 2011, Dr. jur. Rainer Hess
Benefit-package decisions must be justified by an evidence- based process to determine whether services, pharmaceuticals or technologies are medically effective to reach patient relevant objectives: morbidity, mortality and life-quality. Evidence based assessments in Germany only could be used to select the most appropriate (efficient) service etc. from others; if a costly innovation has a significant additional benefit, the sickness funds must pay for it (rationalizing not rationing). Pharmaceutical Policy and Pricing Page 8 | 7th November 2011 | Commonwealth Fund/ Alliance for Health Reform© 2011, Dr. jur. Rainer Hess
“Generic Medicines in the Taiwanese and German Legal Systems” 03 June 2011 in Taipei, Taiwan Role of Generics in the German Health Care System Financial.
School of Public Health Health Economics and Health Care Management University of Bielefeld Bielefeld (Germany), September 29th, 2015 Prof. Dr. Wolfgang.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
The German Health Care System and the Federal Joint Committee (G-BA) Norbert Schmacke FJC/ University of Bremen.
What You Wanted to Know About Formularies Emmanuelle Mirsakov Pharm.D. Candidate 2007 USC School Of Pharmacy.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Portugal Economic Evaluation Applied to Decision Making Isaura Vieira INFARMED, I.P. – National Authority for Medicines and Health Products I Pan-American.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Generic Substitution Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Reimbursement & Pricing in Turkey Association of Research Based Pharmaceutical Companies.
Universal Coverage… “Pharmaceutical Benefit Management” or “Pharmacy Benefit Management” is the set of rules, controls and enforcement tools that define.
Conference: Generic Drugs in Turkey and the EU THE PORTUGUESE MODEL FOR STIMULATING GENERIC COMPETITION IN THE EU June 2, 2005, Ankara, Turkey Rui Santos.
Exhibit ES-1. Key German and Dutch Policies for a Multipayer System, with Insights for U.S. National Reforms Insurance Markets –Insurance exchanges with.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 Price Volume Agreements in the Czech Republic Tomas Sechser Daniela Rrahmaniova.
Medication Management. Outline Medication Management. Formulary System vs. Formulary List. Publishing your Formulary. Formulary Maintenance. Pharmacy.
Right Drug, Right Person, Right Price: Improving and Governing the Provincial Drug System Helen Stevenson Executive Lead, Drug System Secretariat Ministry.
Drug Formulary Development & Management Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2015.
World Health Organization & World Trade Organization Secretariats.
Pricing and Reimbursement Policies 1. Pricing Policies Patented Medicines Maximum retail prices capped by Ministry of Economy (mainly for private sector)
EXPERIENCES IN SOUTH AFRICA WITH THE INTRODUCTION OF PHARMACEUTICAL PRICING LEGISLATION Zokufa HZ, Pillay T Pharmaceutical Policy and Planning, Department.
Focus on the Drug Payment Methods Landscape Academy of Managed Care Pharmacy April 17, 2009.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.
Keith Tolley, Director, Tolley Health Economics Ltd IDF Europe Symposium 30 th September Tolley Health Economics Ltd Strategic Consulting in Health.
ACCESS TO MEDICINES - POLICY AND ISSUES MOH Botswana.
Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 List of Reimbursed Drugs in the Czech Republic Tomas Sechser Daniela Rrahmaniova.
MEDICATION USE IN RURAL AMERICA ASSOCIATION UPDATES National Community Pharmacists Association Tina Schlecht, PharmD, MBA Director, Pharmacy Affairs.
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
Sommaire Innovation Summit Roles for Stakeholders in the Healthcare System July 2010.
PwC Pharmaceutical Drug Pricing and Reporting Issues A Brief Overview of Government Drug Price Reporting Requirements July 28, 2005 National Parma Audioconference.
Avalere Health LLC | The intersection of business strategy and public policy Medicare Prescription Drug Payment Presented by Margaret Nowak September 24,
Understanding Mail Order Community pharmacists provide a valuable service desired by patients. Very rarely are mail order and community pharmacies allowed.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
Technology and Health Care HCA 701 November 10, 2005.
Managed Care Pharmacy Financials January 15, 2015.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Issues and Compliance Strategies Related to Government Pricing Joseph W. Metro.
November 26, Fall Forum Alberta’s Pharmaceutical Strategy and Programs Policy Recommendations.
Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.
The Korus FTA Will Lead to Higher Drug Prices in Korea Mike Palmedo, Research Coordinator Program on Information Justice and Intellectual Property American.
Pricing and paying for medicines Ad Antonisse AstraZeneca BV April 2005.
Pharmacy & National Procurement Christine Gilmour Chief Pharmacist NHS Lanarkshire.
Formulary Manufacturer Contracting Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2015.
Pharmaceutical Society of South Africa The community pharmacy environment HMI Public Hearing Set 1 Hearing 2 Pharmaceutical Society of South Africa.
Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 System of counting of reimbursement costs in the Czech Republic Tomas Sechser.
© 2017 SlidePlayer.com Inc. All rights reserved.